Utility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment

Utilidad de un test de screening (MoCa) para predecir fisiopatología amiloide en deterioro cognitivo leve

dc.creatorClarens, María Florencia
dc.creatorCalandri, Ismael Luis
dc.creatorHelou, Maria Belen
dc.creatorMartín, María-Eugenia
dc.creatorChrem Mendez, Patricio
dc.creatorCrivelli, Lucia
dc.date2023-05-12T21:55:00Z
dc.date2023-05-12T21:55:00Z
dc.date2020-12-09
dc.date.accessioned2023-10-03T19:04:51Z
dc.date.available2023-10-03T19:04:51Z
dc.identifierClarens, M.-F., Calandri, I., Helou, M.-B., Martín, M.-E., Chrem-Méndez, P., & Crivelli, L. (2020). Utility of a Screening Test (MoCa) to Predict Amyloid Physiopathology in Mild Cognitive Impairment: Utilidad de una prueba de cribado (MoCa) para predecir la fisiopatología amiloide en el deterioro cognitivo leve. Journal of Applied Cognitive Neuroscience, 1(1), 87–91. https://doi.org/10.17981/JACN.1.1.2020.13
dc.identifierhttps://hdl.handle.net/11323/10121
dc.identifier10.17981/JACN.1.1.2020.13
dc.identifier2745-0031
dc.identifierCorporación Universidad de la Costa
dc.identifierREDICUC - Repositorio CUC
dc.identifierhttps://repositorio.cuc.edu.co/
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9167461
dc.descriptionIntroduction: The MoCa (Montreal Cognitive Assessment) Screening test has become relevant in recent years in the screening of patients with Mild Cognitive Impairment (MCI). It is important to seek and study simple and reliable tools in clinical practices that correlate with biological markers that have been used to predict conversion from MCI to AD. Objective: To analyze the MOCA and its cognitive sub-scores and the relationship with Amyloid pathophysiology in Alzheimer’s Disease. Methodology: 32 patients with MCI were studied, they were separated according positive (n: 20) and negative (n: 12) underlying amyloid pathology. The patients performed a extensive cognitive assessment that included MoCa Test. Results: MoCa Total Scores showed significantly different results between groups (p < 0.001) and the Orientation Score (MoCa OIS)) (p < 0.05) with worse performance of patients with amyloid pathophysiology. Score of MoCa a cut-off point of < 24 was established, since the diagnostic sensitivity at this point was 83% and the specificity 70%. Conclusions: The MoCa is a useful tool to differentiate biomarker status in MCI. Future studies should study this tool in the prodromal phases of the disease.
dc.descriptionIntroducción: El MoCa (Montreal Cognitive Assesment) ha cobrado relevancia en los últimos años en el cribaje de pacientes con Deterioro Cognitivo Leve (DCL). El uso de herramientas clinicas simples y confiables con alta capacidad de predicción de la conversion del DCL a Enfermedad de Alzheimer (EA) es de gran importancia. Objetivo: Analizar la capacidad del MoCa y sus sub-scores cognitivos para la detección de fisiopatología amiloide en un grupo de pacientes con DCL. Metodología: Se estudiaron 32 pacientes con DCL, se los separó según fisiopatología amiloide subyacente positiva (n:20) y negativa (n:12). Los pacientes realizaron una extensa evaluación cognitiva que incluyó en MoCA. Resultados: El Score Total del MoCa arrojó resultados significativamente diferentes entre grupos (p < 0.001) así como el Score de Memoria (MoCa MIS), el Ejecutivo (MoCa EIS), el Score Atencional (MoCa AIS) ) (p < 0.001) y el de Orientación (MoCa OIS) ) (p < 0.05) obteniendo un peor desempeño los pacientes con fisiopatología amiloide. Se establecio un punto de corte de < 24 para el Score Total del MoCa, ya que la sensibilidad en este punto fue de 83% y la especificidad de 70%. Conclusiones: El MoCa es una herramienta útil para utilizar en pacientes con Deterioro Cognitivo Leve debido a Enfermedad de Alzheimer. Futuros estudios deberían estudiar esta herramienta en las fases prodrómicas de la enfermedad.
dc.format5 páginas
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherCorporación Universidad de la Costa
dc.publisherColombia
dc.relationJournal of Applied Cognitive Neuroscience
dc.relationBesser, L., Kukull, W., Knopman, D. S., Chui, H., Galasko, D., Weintraub, S., Jicha, G., Carlsson, C., Burns, J., Quinn, J., Sweet, R. A., Rascovsky, K., Teylan, M., Beekly, D., Thomas, G., Bollenbeck, M., Monsell, S., Mock, C., Hua, X., Thomas, N., Robichaud, E., Dean, M., Hubbard, J., Jacka, M., Schwabe-Fry, K., Wu, J., Phelps, C. & Morris, J. C. (2018). Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set. Alzheimer disease and associated disorders, 32(4), 351–358. https://doi.org/10.1097/WAD.0000000000000279
dc.relationClarens, M. F., Crivelli, L., Calandri, I., Chrem, P., Martin, M. E., Russo, M. J., Campos, J., Surace, E., Vásquez, S., Sevlever, G. & Allegri, R. F. (2020). Neuropsychological profile of Alzheimer’s disease based on amyloid biomarker findings results from a South American cohort. Applied Neuropsychology: Adult, 1–6. https://doi.org/10.1080/23279095.2020.1756816
dc.relationFolstein, M. F., Folstein, S. E. & McHugh, P. R. (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6
dc.relationHachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Rusell, R. W. & Symon, L. (1975). Cerebral blood flow in dementia. Archives of neurology, 32(9), 632–637. https://doi.org/10.1001/archneur.1975.00490510088009
dc.relationHugues, M., Romey, G., Duval, D., Vincent, J. P. & Lazdunski, M. (1982). Apamin as a selective blocker of the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp and biochemical characterization of the toxin receptor. Proceedings of the National Academy of Sciences, 79(4), 1308–1312. https://doi.org/10.1073/pnas.79.4.1308
dc.relationJulayanont, P., Brousseau, M., Chertkow, H., Phillips, N. & Nasreddine, Z. S. (2014). Montreal Cognitive Assessment Memory Index Score (MoCa-MIS) as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer’s Disease. Journal of the American Geriatrics Society, 62(4), 679–684. https://doi.org/10.1111/jgs.12742
dc.relationNasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCa: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
dc.relationPetersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G. & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of neurology, 56(3), 303–308. https://doi.org/10.1001/archneur.56.3.303
dc.relationWeintraub, S., Besser, L., Dodge, H. H., Teylan, M., Ferris, S., Goldstein, F. C., Kramer, J., Loewenstein, D., Marson, D., Mungas, D., Salmon, D., Welsh-Bohmer, K., Zhou, X.-H., Shirk, S. D., Atri, A., Kukull, W. A., Phelps, C. & Morris, J. C. (2018). Version 3 of the Alzheimer Disease Centers’ neuropsychological test battery in the Uniform Data Set (UDS). Alzheimer disease and associated disorders, 32(1), 10–17. https://doi.org/10.1097/WAD.0000000000000223
dc.relation91
dc.relation87
dc.relation1
dc.relation1
dc.rightsCopyright (c) 2020 Journal of Applied Cognitive Neuroscience
dc.rightsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.sourcehttps://revistascientificas.cuc.edu.co/JACN/article/view/3323
dc.subjectNeuropsychology
dc.subjectDementia
dc.subjectMild cognitive impairment
dc.subjectAlzheimer’s disease
dc.subjectAmyloid
dc.subjectNeuropsicología
dc.subjectDemencia
dc.subjectDeterioro cognitivo leve
dc.subjectEnfermedad de Alzheimer
dc.subjectAmiloide
dc.titleUtility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment
dc.titleUtilidad de un test de screening (MoCa) para predecir fisiopatología amiloide en deterioro cognitivo leve
dc.typeArtículo de revista
dc.typehttp://purl.org/coar/resource_type/c_2df8fbb1
dc.typeText
dc.typeinfo:eu-repo/semantics/article
dc.typehttp://purl.org/redcol/resource_type/ART
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/coar/version/c_970fb48d4fbd8a85


Este ítem pertenece a la siguiente institución